Swiss National Bank Has $7.82 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Swiss National Bank grew its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 1.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,100 shares of the company’s stock after buying an additional 1,700 shares during the period. Swiss National Bank owned approximately 0.19% of PROCEPT BioRobotics worth $7,818,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PRCT. Avior Wealth Management LLC grew its stake in PROCEPT BioRobotics by 6,823.1% in the third quarter. Avior Wealth Management LLC now owns 3,600 shares of the company’s stock valued at $288,000 after acquiring an additional 3,548 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of PROCEPT BioRobotics in the 3rd quarter valued at approximately $1,371,000. Advisors Asset Management Inc. increased its stake in PROCEPT BioRobotics by 28.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 12,350 shares of the company’s stock worth $989,000 after purchasing an additional 2,758 shares in the last quarter. Intech Investment Management LLC acquired a new stake in PROCEPT BioRobotics during the 3rd quarter worth approximately $979,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in PROCEPT BioRobotics by 13.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 402,565 shares of the company’s stock valued at $32,254,000 after buying an additional 46,665 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PRCT. Truist Financial restated a “buy” rating and set a $90.00 price objective (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Morgan Stanley reduced their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $94.29.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $58.10 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The business has a 50-day moving average of $67.15 and a 200-day moving average of $78.34. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of -29.79 and a beta of 1.05. PROCEPT BioRobotics Co. has a fifty-two week low of $45.56 and a fifty-two week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, sell-side analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).